We bring you the latest news from the healthcare about the health care in the United Kingdom.

zaterdag 18 augustus 2018

Journal of Patient Safety and Risk Management Vol. 23, No. 4, August 2018 is now available online

Table of Contents Alert
Journal of Patient Safety and Risk Management- Volume: 23, Number: 4 (August 2018)
Editorial and Comment
The easy part is over: Creating safe systems of care
The role of the patient in patient safety: What can we learn from healthcare's history? and
Original Research
Value-based purchasing may unfairly penalize specialty centers performing combined liver–colon multivisceral resections , , , and
Medicolegal
A British doctor's duty to offer help in emergencies outside of a clinical setting
Policy
Operating management system for high reliability: Leadership, accountability, learning and innovation in healthcare , , , , , , , , and
Creating a comprehensive, unit-based approach to detecting and preventing harm in the neonatal intensive care unit , , , , , , , , , , , , , and

This message was sent to dezorgsector.uk@gmail.com. Unsubscribe from this alert or manage your alerts from SAGE Journals.

SAGE Publishing * 2455 Teller Road * Thousand Oaks, CA 91320 * U.S.A.

Privacy Policy

© 2018 SAGE Journals. All Rights Reserved.

The Lancet: [Articles] Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogrou...

[Articles] Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
The adjuvanted and non-adjuvanted NmCV-5 vaccines were well tolerated and did not produce concerning adverse effects and resulted in immune responses that are predicted to confer protection against all five targeted serogroups of invasive meningococcal disease. Further clinical testing of NmCV-5 is ongoing, and additional clinical trials are necessary to confirm the safety and immunogenicity of NmCV-5 in target populations.
Read more

[Comment] NmCV-5 meningococcal vaccine: Neisseria meningitidis' nemesis?
Major progress has occurred during the past 20 years in the prevention of meningitis globally, mainly through the development, marketing, and large public health use of potent, life-saving vaccines. However, meningitis remains a major public health challenge with the global number of deaths from meningitis recently estimated to be over 300 000 among the population under 5 years of age,1 with devastating, long-term sequelae in many survivors. Developing countries suffer from the highest burden by far, while they are faced with the biggest challenges in accessing vaccines, diagnostics, and care.
Read more

[Personal View] Sustainable access to deworming drugs in a changing landscape
The global effort to control and eliminate soil-transmitted helminthiasis (STH) currently depends on donations of albendazole and mebendazole, which reached more than 530 million children in 2016. As we approach 2020, the WHO goal of eliminating STH as a public health problem will not be met in most endemic countries, and ongoing treatment will be necessary. Additionally, the volume of drugs required might increase because global strategies for STH aim to interrupt transmission. Under the 2012 London Declaration on Neglected Tropical Diseases, pharmaceutical company commitments to donate drugs to control or eliminate neglected tropical diseases extend to 2020.
Read more

[Media Watch] We were there
Sometimes people who make a difference in an outbreak response are not those who are officially in charge or appear regularly in the headlines. Such is the case of Oliver Johnson and Sinead Walsh, who found themselves in Sierra Leone in 2014, just when the Ebola virus disease outbreak started. Oliver and Sinead—because after reading the book, you will want to call them by their first names and have them as friends—discuss their experience of two complementary fronts of the response to the outbreak in their book Getting to zero: a doctor and a diplomat on the Ebola frontline.
Read more

[Articles] Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of electronic health records
Increases in E coli bloodstream infections in Oxfordshire are primarily community associated, with substantial co-amoxiclav resistance; nevertheless, we found little or no change in mortality. Focusing interventions on primary care facilities, particularly those with high co-amoxiclav use, could be effective in reducing the incidence of co-amoxiclav-resistant E coli bloodstream infections, in this region and more generally.
Read more

vrijdag 17 augustus 2018

WHO: Ebola virus disease – Democratic Republic of the Congo

Ebola virus disease – Democratic Republic of the Congo
On 1 August 2018, the Ministry of Health (MoH) of the Democratic Republic of the Congo declared a new outbreak of Ebola virus disease (EVD) in the town of Mangina, Mabalako Health Zone, North Kivu Province.
Read more

Nature Reviews Nephrology - Table of Contents alert Volume 14 Issue 9

Nature Reviews Nephrology
TABLE OF CONTENTS

September 2018 Volume 14, Issue 9

Research Highlights
News & Views
Reviews
Perspectives
 
Advertisement
Nature Reviews Reader Survey

At Nature Reviews we are continually looking for ways to ensure we meet our readers' needs. Your responses to this short survey will give us insight into how our content may be improved.

Get started here.

 

Research Highlights

 
Targeting ARNT to attenuate renal fibrosis
Susan J. Allison

p535 | doi:10.1038/s41581-018-0038-y
PDF


 
Immune networks in CI-AKI
Susan J. Allison

p536 | doi:10.1038/s41581-018-0036-0
PDF


 
RHO-like GTPases in nephrotic syndrome
Grant Otto

p536 | doi:10.1038/s41581-018-0030-6
PDF


 
Regulation of nephrogenesis
Ellen Carney

p536 | doi:10.1038/s41581-018-0033-3
PDF


 
 

News & Views

 
Preserving kidney health during intensive blood pressure control
Maria Luisa S. Sequeira-Lopez & R. Ariel Gomez

pp537 - 538 | doi:10.1038/s41581-018-0034-2
PDF


 
The origin, evolution and route to metastasis of clear cell RCC
Christopher J. Ricketts & W. Marston Linehan

pp538 - 540 | doi:10.1038/s41581-018-0031-5
PDF


 
 
Nature Reviews Nephrology
EVENT
2nd International Conference on Nephrology
20.09.18
Toronto, Canada
More science events from
Advertisement
Do you have a career question?

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud.

Listen today!
 

Reviews

 
Intravenous fluid therapy in critically ill adults   
Simon Finfer, John Myburgh & Rinaldo Bellomo

pp541 - 557 | doi:10.1038/s41581-018-0044-0
This Review updates the evidence base for the administration of intravenous fluids to critically ill patients. Finfer and colleagues also discuss unresolved questions, such as whether buffered solutions are better than normal saline, and the benefits and harms of restrictive approaches to fluid administration.
Full Text | PDF


 
HLA in transplantation   
Robert A. Montgomery, Vasishta S. Tatapudi, Mary S. Leffell & Andrea A. Zachary

pp558 - 570 | doi:10.1038/s41581-018-0039-x
Improved understanding of HLAs together with advances in HLA typing and antibody detection techniques have enabled transplantation of sensitized patients. Here, the authors discuss these advances as well as novel approaches to desensitization, immunomodulation and tolerance induction.
Full Text | PDF


 
Cardiorenal complications of immune checkpoint inhibitors   
Krishna Sury, Mark A. Perazella & Anushree C. Shirali

pp571 - 588 | doi:10.1038/s41581-018-0035-1
Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy; however, these agents can induce immune-related adverse events (irAEs) in off-target organs. This Review describes the mechanism of action of ICI therapies and how these agents induce irAEs in the kidney and heart.
Full Text | PDF
Collection: Cancer at Nature Research

 
Advertisement
Searching for a new career? 

At Nature Research we frequently recruit talented individuals to join our editorial and publishing teams. If you have a PhD and a passion for science this may be the perfect career for you.

Visit our research editorial and publishing careers website to discover more about what we do.
 

Perspectives

 
The role of B7-1 in proteinuria of glomerular origin   
Rubina Novelli, Ariela Benigni & Giuseppe Remuzzi

pp589 - 596 | doi:10.1038/s41581-018-0037-z
This Perspectives article describes supporting and contradicting data regarding the role of podocyte B7-1 in the pathogenesis of various podocytopathies and highlights issues that need to be addressed to standardize approaches to the study of this protein.
Full Text | PDF


 
Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature